MA25325A1 - Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. - Google Patents

Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Info

Publication number: MA25325A1
Authority: MA; Morocco
Prior art keywords: formulation; production method; same; multiple units; units containing
Prior art date: 1998-11-11

Application number

MA26228A

Other languages

English (en)

Inventor

Anders Ringberg

Torkel Gren

Martin Wikberg

Randy J Wald

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-11

Filing date

2001-06-08

Publication date

2001-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-08-26 Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/fr

2001-06-08 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

2001-12-31 Publication of MA25325A1 publication Critical patent/MA25325A1/fr

Links

239000002775 capsule Substances 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA26228A 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. MA25325A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9803871A SE9803871D0 (sv)	1998-11-11	1998-11-11	Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (fr)	1998-08-27	1999-08-26	Formulation de tolterodine therapeutique a liberation controlee

Publications (1)

Publication Number	Publication Date
MA25325A1 true MA25325A1 (fr)	2001-12-31

Family

ID=20413266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26228A MA25325A1 (fr)	1998-11-11	2001-06-08	Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Country Status (40)

Country	Link
US (1)	US6911217B1 (fr)
EP (1)	EP1128819B1 (fr)
JP (1)	JP3616011B2 (fr)
KR (1)	KR100467384B1 (fr)
CN (1)	CN1169522C (fr)
AP (1)	AP1323A (fr)
AR (1)	AR027815A1 (fr)
AT (1)	ATE247458T1 (fr)
AU (1)	AU762410B2 (fr)
BG (1)	BG65149B1 (fr)
BR (1)	BRPI9915142B8 (fr)
CA (1)	CA2350061C (fr)
CZ (1)	CZ299582B6 (fr)
DE (1)	DE69910604T2 (fr)
DK (1)	DK1128819T3 (fr)
EA (1)	EA005074B1 (fr)
EE (1)	EE05232B1 (fr)
ES (1)	ES2204193T3 (fr)
GE (1)	GEP20022833B (fr)
HK (1)	HK1040917B (fr)
HR (1)	HRP20010333B1 (fr)
HU (1)	HU226582B1 (fr)
ID (1)	ID30039A (fr)
IL (1)	IL142809A0 (fr)
IS (1)	IS2370B (fr)
MA (1)	MA25325A1 (fr)
MY (1)	MY122195A (fr)
NO (1)	NO331399B1 (fr)
NZ (1)	NZ511430A (fr)
OA (1)	OA11673A (fr)
PL (1)	PL195780B1 (fr)
PT (1)	PT1128819E (fr)
RS (1)	RS49891B (fr)
SE (1)	SE9803871D0 (fr)
SI (1)	SI1128819T1 (fr)
SK (1)	SK284758B6 (fr)
TW (2)	TWI222879B (fr)
UA (1)	UA57165C2 (fr)
WO (1)	WO2000027364A1 (fr)
ZA (1)	ZA200103575B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6310103B1 (en) *	1996-07-19	2001-10-30	Bridge Pharma, Inc.	S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en)	1997-07-08	2013-10-22	The Iams Company	Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (fr)	1998-05-12	1999-11-17	Schwarz Pharma Ag	Dérivés de 3,3-diphénylpropylamines
DK1227806T3 (da)	1999-11-11	2005-10-31	Pfizer Health Ab	Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
CA2496806A1 (fr) *	2002-08-28	2004-03-11	Pharmacia Corporation	Composition liquide de tolterodine administree par voie orale
US8168170B2 (en)	2002-10-03	2012-05-01	The Procter And Gamble Company	Compositions having an inner core and at least three surrounding layers
AU2004206110A1 (en) *	2003-01-22	2004-08-05	Pfizer Health Ab	Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) *	2003-04-08	2004-11-18	Schwarz Pharma Ag	Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (fr)	2003-06-26	2004-12-29	Isa Odidi	Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US8709476B2 (en)	2003-11-04	2014-04-29	Supernus Pharmaceuticals, Inc.	Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (fr)	2003-11-04	2011-02-17	Supernus Pharmaceuticals Inc
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en)	2003-12-19	2010-08-31	The Procter & Gamble Company	Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en)	2003-12-19	2005-07-14	The Procter & Gamble Company	Canine probiotic Bifidobacteria globosum
US8894991B2 (en)	2003-12-19	2014-11-25	The Iams Company	Canine probiotic Lactobacilli
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
US8394409B2 (en) *	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (fr)	2004-08-27	2006-03-01	KRKA, D.D., Novo Mesto	Composition pharmaceutique de tolterodine avec liberation soutenue
CA2590556A1 (fr) *	2005-01-10	2006-07-13	Teva Pharmaceutical Industries Ltd.	Procedes permettant de preparer du tartrate de tolterodine
JP4938006B2 (ja)	2005-05-31	2012-05-23	ザ・アイムス・カンパニー	ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (fr)	2005-05-31	2010-12-15	The Iams Company	Lactobacilles probiotiques félins
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
DK2997953T3 (en)	2006-01-18	2019-04-15	Intec Pharma Ltd	ADMINISTRATION ORAL ADMINISTRATION
PT3095447T (pt)	2006-02-03	2022-01-24	Opko Renal Llc	Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
KR100714058B1 (ko) *	2006-02-06	2007-05-02	한국유나이티드제약 주식회사	톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
MX2008010877A (es) *	2006-02-24	2008-11-25	Teva Pharma	Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion.
EP1996169A2 (fr) *	2006-03-21	2008-12-03	Teva Pharmaceutical Industries Ltd	Formule à libération contrôlée de toltérodine
EP1839649A1 (fr) *	2006-03-31	2007-10-03	LEK Pharmaceuticals D.D.	Formulations enrobées pour tolterodine
CN104825397A (zh) *	2006-04-03	2015-08-12	伊萨·奥迪迪	含有机溶胶涂层的受控释放递送物件
EP2015735A1 (fr) *	2006-04-21	2009-01-21	Synthon B.V.	Perles de tolterodine
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
WO2007131804A1 (fr)	2006-05-17	2007-11-22	Synthon B.V.	Composition en comprimé pour la libération prolongée de la tamsulosine
DK2037936T3 (da)	2006-06-21	2014-09-22	Opko Renal Llc	Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
JP2008007458A (ja) *	2006-06-29	2008-01-17	Freunt Ind Co Ltd	レイヤリング用核粒子とその製造方法
CA2670636A1 (fr)	2006-11-27	2008-06-05	H. Lundbeck A/S	Derives d'heteroaryl-amides
WO2008093303A2 (fr)	2007-02-01	2008-08-07	The Iams Company	Procédé de réduction de l'inflammation et du stress chez un mammifère
KR101691876B1 (ko)	2007-04-25	2017-01-02	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (fr)	2007-04-25	2018-03-06	Cytochroma Inc.	Procede de traitement d'une insuffisance et d'une carence en vitamine d
ES3047207T3 (en)	2007-04-25	2025-12-03	Opko Renal Llc	Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CL2008001970A1 (es) *	2007-07-03	2009-03-27	Synthon Bv	Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
US8486452B2 (en)	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations
US8871275B2 (en)	2007-08-08	2014-10-28	Inventia Healthcare Private Limited	Extended release compositions comprising tolterodine
CN105534936B (zh)	2007-08-13	2020-07-31	Ohemo 生命科学股份有限公司	抗滥用药物、使用方法和制备方法
US20090192228A1 (en) *	2008-01-28	2009-07-30	Actavis Group Ptc Ehf	Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) *	2008-02-26	2009-08-27	Lai Felix S	Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (fr) *	2008-04-01	2009-10-01	Pharmascience Inc.	Nouvelles formulations pharmaceutiques orales a liberation controlee
ES2593356T3 (es)	2008-04-02	2016-12-07	Opko Ireland Global Holdings, Ltd.	Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US20090311317A1 (en) *	2008-05-14	2009-12-17	Capricorn Pharma Inc.	Modified release tolterodine formulations
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
US8465770B2 (en)	2008-12-24	2013-06-18	Synthon Bv	Low dose controlled release tablet
WO2011013082A1 (fr)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Compositions pharmaceutiques à unités multiples multi-couches
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
WO2011061616A2 (fr)	2009-11-23	2011-05-26	Micro Labs Limited	Compositions à libération prolongée contenant de la toltérodine et procédé de préparation de celles-ci
WO2011095388A1 (fr)	2010-02-04	2011-08-11	Synthon Bv	Microgranule de toltérodine
US11672809B2 (en)	2010-03-29	2023-06-13	Eirgen Pharma Ltd.	Methods and compositions for reducing parathyroid levels
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
BR112012024432A2 (pt)	2010-03-29	2016-05-31	Ferring Bv	composição farmacêutica de dissolução rápida
CA2796877A1 (fr)	2010-04-30	2011-11-03	Merck Sharp & Dohme Corp.	Nouveaux agonistes du recepteur beta 3 adrenergique
US20120040008A1 (en) *	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el)	2011-07-27	2012-06-29	Φαρματεν Αβεε,	Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6174585B2 (ja)	2011-09-16	2017-08-02	フェリングベスローテンフェンノートシャップ	速溶性医薬組成物
WO2013047795A1 (fr) *	2011-09-30	2013-04-04	アステラス製薬株式会社	Composition pharmaceutique granulaire
BR112015000329A2 (pt)	2012-07-12	2017-06-27	Ferring Bv	formulações de diclofenac
HK1213178A1 (zh) *	2012-09-20	2016-06-30	Ohr Pharma, Llc	用於治疗剂的缓释的多层生物可降解的微粒
US20150306170A1 (en) *	2012-11-21	2015-10-29	Ferring B.V.	Composition for immediate and extended release
TW201422254A (zh) *	2012-11-21	2014-06-16	Ferring Bv	用於速釋及延釋的組成物
HUE050303T2 (hu) *	2013-03-13	2020-11-30	Intervet Int Bv	Stabil bioaktív szubsztanciák és eljárások elõállítására
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
US20140275038A1 (en)	2013-03-15	2014-09-18	Inspirion Delivery Technologies, Llc	Abuse deterrent compositions and methods of use
AU2014246617A1 (en)	2013-12-23	2015-07-09	Sun Pharmaceutical Industries Limited	Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en)	2014-09-15	2020-08-04	Ohemo Life Sciences Inc.	Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (fr) *	2014-10-31	2016-04-30	Purdue Pharma	Methodes et compositions destinees au traitement du trouble de deficit d'attention
WO2017146053A1 (fr) *	2016-02-23	2017-08-31	ニプロ株式会社	Particules de composition pharmaceutique et préparation se délitant par voie orale comprenant celles-ci
KR20180123100A (ko)	2016-03-28	2018-11-14	옵코 아일랜드 글로벌 홀딩스 리미티드	비타민 d 치료 방법
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1144911B (it) *	1981-03-19	1986-10-29	Pharmatec Spa	Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja)	1993-10-08	1995-04-21	Hitachi Ltd	情報通信装置
JP3453186B2 (ja)	1994-04-14	2003-10-06	共和薬品工業株式会社	徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) *	1994-07-08	1994-07-08	Astra Ab	New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) *	1994-10-06	1997-07-08	Ortho Pharmaceutical Corporation	Multilayered controlled release pharmaceutical dosage form
US5567441A (en) *	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
US6310103B1 (en)	1996-07-19	2001-10-30	Bridge Pharma, Inc.	S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) *	1998-07-07	2001-11-06	Cascade Development, Inc.	Sustained release pharmaceutical preparation

1998
- 1998-11-11 SE SE9803871A patent/SE9803871D0/xx unknown
1999
- 1999-11-11 WO PCT/SE1999/002052 patent/WO2000027364A1/fr not_active Ceased
- 1999-11-11 IL IL14280999A patent/IL142809A0/xx unknown
- 1999-11-11 DE DE69910604T patent/DE69910604T2/de not_active Expired - Lifetime
- 1999-11-11 MY MYPI99004911A patent/MY122195A/en unknown
- 1999-11-11 AT AT99971702T patent/ATE247458T1/de active
- 1999-11-11 CN CNB998132160A patent/CN1169522C/zh not_active Expired - Lifetime
- 1999-11-11 US US09/763,281 patent/US6911217B1/en not_active Expired - Lifetime
- 1999-11-11 EE EEP200100254A patent/EE05232B1/xx unknown
- 1999-11-11 ES ES99971702T patent/ES2204193T3/es not_active Expired - Lifetime
- 1999-11-11 NZ NZ511430A patent/NZ511430A/en not_active IP Right Cessation
- 1999-11-11 AR ARP990105734A patent/AR027815A1/es active IP Right Grant
- 1999-11-11 PL PL99348612A patent/PL195780B1/pl unknown
- 1999-11-11 PT PT99971702T patent/PT1128819E/pt unknown
- 1999-11-11 HK HK02102521.2A patent/HK1040917B/zh not_active IP Right Cessation
- 1999-11-11 AP APAP/P/2001/002166A patent/AP1323A/en active
- 1999-11-11 ID IDW00200101038A patent/ID30039A/id unknown
- 1999-11-11 JP JP2000580595A patent/JP3616011B2/ja not_active Expired - Lifetime
- 1999-11-11 DK DK99971702T patent/DK1128819T3/da active
- 1999-11-11 UA UA2001042824A patent/UA57165C2/uk unknown
- 1999-11-11 OA OA1200100112A patent/OA11673A/en unknown
- 1999-11-11 GE GEAP19995939A patent/GEP20022833B/en unknown
- 1999-11-11 RS YUP-331/01A patent/RS49891B/sr unknown
- 1999-11-11 CZ CZ20011627A patent/CZ299582B6/cs not_active IP Right Cessation
- 1999-11-11 KR KR10-2001-7005879A patent/KR100467384B1/ko not_active Expired - Lifetime
- 1999-11-11 CA CA002350061A patent/CA2350061C/fr not_active Expired - Lifetime
- 1999-11-11 SI SI9930411T patent/SI1128819T1/xx unknown
- 1999-11-11 HR HR20010333A patent/HRP20010333B1/xx not_active IP Right Cessation
- 1999-11-11 EA EA200100538A patent/EA005074B1/ru not_active IP Right Cessation
- 1999-11-11 EP EP99971702A patent/EP1128819B1/fr not_active Expired - Lifetime
- 1999-11-11 SK SK625-2001A patent/SK284758B6/sk not_active IP Right Cessation
- 1999-11-11 BR BRPI9915142A patent/BRPI9915142B8/pt not_active IP Right Cessation
- 1999-11-11 HU HU0105038A patent/HU226582B1/hu unknown
- 1999-11-11 AU AU14366/00A patent/AU762410B2/en not_active Expired
2000
- 2000-02-11 TW TW089102338A patent/TWI222879B/zh not_active IP Right Cessation
- 2000-02-11 TW TW089102332A patent/TWI267385B/zh not_active IP Right Cessation
2001
- 2001-05-03 ZA ZA200103575A patent/ZA200103575B/en unknown
- 2001-05-09 IS IS5936A patent/IS2370B/is unknown
- 2001-05-10 NO NO20012314A patent/NO331399B1/no not_active IP Right Cessation
- 2001-06-08 BG BG105582A patent/BG65149B1/bg unknown
- 2001-06-08 MA MA26228A patent/MA25325A1/fr unknown

Also Published As

Publication number	Publication date
TWI267385B (en)	2006-12-01
IS2370B (is)	2008-06-15
WO2000027364A1 (fr)	2000-05-18
AU762410B2 (en)	2003-06-26
DE69910604T2 (de)	2004-06-24
NO20012314L (no)	2001-07-09
UA57165C2 (uk)	2003-06-16
JP2003517446A (ja)	2003-05-27
EE200100254A (et)	2002-12-16
KR100467384B1 (ko)	2005-01-24
CZ20011627A3 (cs)	2001-10-17
EP1128819A1 (fr)	2001-09-05
EA005074B1 (ru)	2004-10-28
ES2204193T3 (es)	2004-04-16
SK284758B6 (sk)	2005-11-03
DE69910604D1 (de)	2003-09-25
PL195780B1 (pl)	2007-10-31
NO20012314D0 (no)	2001-05-10
PT1128819E (pt)	2003-12-31
EA200100538A1 (ru)	2001-10-22
BG105582A (en)	2001-12-29
CN1326339A (zh)	2001-12-12
OA11673A (en)	2005-01-12
SI1128819T1 (en)	2003-12-31
HRP20010333A2 (en)	2003-04-30
GEP20022833B (en)	2002-11-25
KR20010075695A (ko)	2001-08-09
AU1436600A (en)	2000-05-29
TWI222879B (en)	2004-11-01
CA2350061A1 (fr)	2000-05-18
MY122195A (en)	2006-03-31
AR027815A1 (es)	2003-04-16
NZ511430A (en)	2003-05-30
RS49891B (sr)	2008-08-07
ZA200103575B (en)	2002-05-03
CN1169522C (zh)	2004-10-06
HRP20010333B1 (en)	2004-10-31
YU33101A (sh)	2003-10-31
NO331399B1 (no)	2011-12-19
DK1128819T3 (da)	2003-12-01
US6911217B1 (en)	2005-06-28
IL142809A0 (en)	2002-03-10
SE9803871D0 (sv)	1998-11-11
HK1040917A1 (en)	2002-06-28
HK1040917B (zh)	2005-05-27
EP1128819B1 (fr)	2003-08-20
PL348612A1 (en)	2002-06-03
EE05232B1 (et)	2009-12-15
IS5936A (is)	2001-05-09
ATE247458T1 (de)	2003-09-15
AP2001002166A0 (en)	2001-06-30
HUP0105038A2 (en)	2002-06-29
CZ299582B6 (cs)	2008-09-10
AP1323A (en)	2004-11-05
SK6252001A3 (en)	2002-01-07
BR9915142A (pt)	2001-08-07
HUP0105038A3 (en)	2006-07-28
ID30039A (id)	2001-11-01
CA2350061C (fr)	2005-05-17
BRPI9915142B8 (pt)	2021-05-25
BG65149B1 (bg)	2007-04-30
JP3616011B2 (ja)	2005-02-02
HU226582B1 (en)	2009-04-28
BRPI9915142B1 (pt)	2015-08-25

Publication	Publication Date	Title
NO993519L (no)	1999-09-16	Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
MXPA03007712A (es)	2004-03-16	Sales farmaceuticas.
DE69102531D1 (de)	1994-07-21	Mikrokapseln, Verkapselungsverfahren und Methode zur Anwendung derselben.
MXPA03005018A (es)	2003-09-25	Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos, y su uso.
MXPA03005019A (es)	2003-09-25	Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
HUP0102921A3 (en)	2002-12-28	Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
DE3679920D1 (de)	1991-08-01	Spiro-3-heteroazolidinverbindungen und ihre salze, ihre herstellung und diese enthaltende pharmazeutische mittel.
FI954111L (fi)	1995-09-01	Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI943688L (fi)	1995-03-21	Uudet 11-bentsaldoksiimi-17beta-metoksi-27alfa-metoksi-metyyli-estradieenijohdannaiset, menetelmät niiden valmistamiseksi ja näitä sisältävät lääkeaineet
ZA983792B (en)	1999-11-08	New cysteine derivatives, processes for their production, and pharmaceuticals containing them.
NO880473L (no)	1988-08-05	Fremgangsmaate til fremstilling av substituerte 3,4-dihydro-2h-benzopyraner og deres anvendelse som legemiddel.
NO883465D0 (no)	1988-08-04	Fremgangsmaate og mellomprodukter for fremstilling av 1-fenyl-3-(1-piperazinyl)-1h-indazoler, og anvendelse derav som medikamenter.
FI970095A7 (fi)	1997-01-10	Uudet kemialliset yhdisteet, niiden valmistus ja niiden käyttö lääkeai neena
NO982754L (no)	1998-08-13	Fosfolipidderivater av fosfonokarboksylsyrer, fremstilling av slike derivater og anvendelse av derivatene som antivirusmedikamenter
NO306156B1 (no)	1999-09-27	Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse
FI961938L (fi)	1996-05-07	Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI951631L (fi)	1995-04-05	Substituoituja kynureniinejä, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
DE3481057D1 (de)	1990-02-22	2-sulfamoylbenzo(b)thiophen-derivate, ihre herstellung und pharmazeutische zubereitung zur behandlung von erhoehtem augeninnendruck.
NO904576L (no)	1991-04-25	Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
ATE125541T1 (de)	1995-08-15	Reine kristalline form von rifapentin.
NO903347L (no)	1991-01-29	14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
ATE32882T1 (de)	1988-03-15	Phenylnonatetraensaeurederivate, ihre herstellung und pharmazeutische praeparate mit diesen derivaten.
PT1001942E (pt)	2003-11-28	Poli-hidroxibutilpirazinas sua preparacao e medicamentos que as contem
FI944751L (fi)	1995-04-12	Heteroaryylipiperidiinejä, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
NO894516L (no)	1990-05-15	Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.